[{"data":1,"prerenderedAt":184},["ShallowReactive",2],{"drug-fesoterodine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":74,"warnings":84,"renal":92,"monitoring":102,"interactions":103,"review":104,"examples":107,"atc":118,"iran":120,"links":127,"populations":144,"usApproval":179},"fesoterodine",1,{"fa":7,"en":8},"فزوترودین","Fesoterodine","genitourinary-sex-hormones",{"fa":11,"en":12},"آنتی‌موسکارینی","Antimuscarinic",[14],{"name":15,"market":16},"Toviaz","US",[18,19,7],"toviaz","توویاز",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"er-4","tablet","oral","4 mg ER tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},4,"mg",false,[16],[32],{"source":33,"section":34},"fda-toviaz","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"er-8","8 mg ER tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},8,[16],[42],{"source":33,"section":34},[44,59],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":56},"oab","overactive-bladder",{"fa":48,"en":49},"مثانه بیش‌فعال بزرگسال — ۴ mg یک بار؛ تا ۸ mg","Overactive bladder, adults — 4 mg once daily; up to 8 mg",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":5},[57],{"source":33,"section":58},"2.1",{"id":60,"disease":61,"label":62,"population":65,"type":54,"unit":28,"dose":70,"refs":71},"ndo","neurogenic-bladder",{"fa":63,"en":64},"بیش‌فعالی دترسور نوروژنیک کودک ۶ سال به بالا و >۲۵ kg — ۴ mg یک بار؛ بالای ۳۵ kg پس از یک هفته ۸ mg","Neurogenic detrusor overactivity, children ≥6 y and >25 kg — 4 mg once daily; >35 kg increase to 8 mg after one week",{"minAge":66,"maxAge":68,"minWeightKg":69},{"value":67,"unit":53},6,{"value":52,"unit":53},25.01,{"perDose":27,"perDoseMax":39,"dosesPerDay":5},[72],{"source":33,"section":73},"2",[75],{"id":76,"severity":77,"text":78,"refs":81},"ci","block",{"fa":79,"en":80},"حساسیت به فزوترودین یا تولترودین؛ احتباس ادرار؛ احتباس معده؛ گلوکوم زاویه بسته کنترل‌نشده.","Hypersensitivity to fesoterodine or tolterodine; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma.",[82],{"source":33,"section":83},"4",[85],{"text":86,"refs":89},{"fa":87,"en":88},"آنژیوادم؛ احتباس ادرار؛ کاهش حرکات گوارش؛ عوارض CNS؛ تشدید میاستنی گراو.","Angioedema; urinary retention; decreased GI motility; CNS effects; worsening myasthenia gravis.",[90],{"source":33,"section":91},"5",[93],{"egfrBelow":94,"severity":95,"text":96,"refs":99},30,"warn",{"fa":97,"en":98},"بزرگسال ClCr ۱۵ تا ۲۹: حداکثر ۴ mg؛ کمتر طبق جدول ۱.","Adults CrCl 15–29: max 4 mg; lower per Table 1.",[100],{"source":33,"section":101},"2.3, Table 1",[],[],{"status":105,"reviewer":106,"date":106},"unverified",null,[108,113],{"regimen":45,"formulation":22,"input":109,"expect":112},{"ageYears":110,"weightKg":111},60,70,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},{"regimen":60,"formulation":22,"input":114,"expect":117},{"ageYears":115,"weightKg":116},10,40,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},[119],"G04BD11",{"status":121,"refs":122},"not-found",[123],{"source":124,"section":125,"url":126},"darooyab-generic","G-4916\u002FFesoterodine","https:\u002F\u002Fwww.darooyab.ir\u002FG-4916\u002FFesoterodine",[128,132,136,139,142],{"kind":129,"url":130,"label":131},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022030","NDA022030",{"kind":133,"url":134,"label":135},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5be745f0-8ae7-4c3c-9962-37d6263326f1","FDA Toviaz",{"kind":137,"url":138,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609021.html",{"kind":140,"url":141,"label":119},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G04BD11",{"kind":143,"url":126,"label":8},"darooyab",{"pregnancy":145,"lactation":154,"pediatric":162,"geriatric":170},{"level":146,"text":147,"quote":150,"refs":151},"caution",{"fa":148,"en":149},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data with the use of Toviaz in pregnant women and adolescents to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",[152],{"source":33,"section":153},"8.1",{"level":146,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information on the presence of fesoterodine in human milk, the effects on the breastfed child, or the effects on milk production.",[160],{"source":33,"section":161},"8.2",{"level":146,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of Toviaz have been established for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 6 years and older and weighing greater than 25 kg.",[168],{"source":33,"section":169},"8.4",{"level":171,"text":172,"quote":175,"refs":176},"ok",{"fa":173,"en":174},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dose adjustment is recommended for the elderly.",[177],{"source":33,"section":178},"8.5",{"kind":180,"refs":181,"id":131},"NDA",[182],{"source":33,"section":183},"SPL approval \u002F marketing category",1792444398795]